Identification

Name
Nepafenac
Accession Number
DB06802
Type
Small Molecule
Groups
Approved
Description

Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Structure
Thumb
Synonyms
  • 2-amino-3-Benzoylbenzeneacetamide
  • AHR 9434
  • AL 6515
  • Amfenac amide
  • Nepafenaco
  • Nepafenacum
External IDs
AHR-9434 / AL-6515
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IlevroSuspension3 mg/mLOphthalmicAlcon, Inc.2012-12-20Not applicableUs
IlevroSuspension0.3 %OphthalmicNovartis2014-06-01Not applicableCanada
NevanacSuspension1 mg/mLOphthalmicPhysicians Total Care, Inc.2011-08-31Not applicableUs
NevanacSuspension0.1 %OphthalmicNovartis2008-08-21Not applicableCanada
NevanacSuspension / drops1 mg/mLOphthalmicAlcon, Inc.2005-09-06Not applicableUs
International/Other Brands
Nevanac
Categories
UNII
0J9L7J6V8C
CAS number
78281-72-8
Weight
Average: 254.2839
Monoisotopic: 254.105527702
Chemical Formula
C15H14N2O2
InChI Key
QEFAQIPZVLVERP-UHFFFAOYSA-N
InChI
InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
IUPAC Name
2-(2-amino-3-benzoylphenyl)acetamide
SMILES
NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N

Pharmacology

Indication

For the treatment of pain and inflammation associated with cataract surgery.

Structured Indications
Pharmacodynamics

Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours postdose, respectively, following bilateral topical ocular TID dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration.

Mechanism of action

Nepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity.

TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
UProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).

Volume of distribution
Not Available
Protein binding

Amfenac has high affinity toward serum albumin proteins. In vitro, the percent bound to human albumin and human serum was 95.4% and 99.1% respectively.

Metabolism

Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation.

Route of elimination

After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine.

Half life
Not Available
Clearance
Not Available
Toxicity

Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

Affected organisms
Not Available
Pathways
PathwayCategory
Nepafenac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nepafenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabNepafenac may increase the anticoagulant activities of Abciximab.Approved
AcebutololNepafenac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNepafenac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinNepafenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Aldosterone.Experimental, Investigational
AldoxorubicinNepafenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alendronic acid.Approved
AliskirenNepafenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alminoprofen.Experimental
AlprenololNepafenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nepafenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Amcinonide.Approved
AmikacinNepafenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNepafenac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinNepafenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNepafenac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nepafenac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Nepafenac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Anisodamine.Investigational
AnnamycinNepafenac may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Antipyrine.Approved
Antithrombin III humanNepafenac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanNepafenac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Nepafenac is combined with Apocynin.Investigational
ApramycinNepafenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Nepafenac is combined with Apremilast.Approved, Investigational
ArbekacinNepafenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNepafenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNepafenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNepafenac may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Atamestane.Investigational
AtenololNepafenac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nepafenac.Approved
BalsalazideNepafenac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminNepafenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNepafenac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNepafenac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nepafenac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nepafenac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nepafenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Betamethasone.Approved, Vet Approved
BetaxololNepafenac may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nepafenac.Approved, Investigational
BevantololNepafenac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nepafenac.Approved, Investigational
BisoprololNepafenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNepafenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNepafenac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bucillamine.Investigational
BucindololNepafenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bufexamac.Experimental
BufuralolNepafenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bumadizone.Experimental
BumetanideNepafenac may decrease the diuretic activities of Bumetanide.Approved
BupranololNepafenac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nepafenac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nepafenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nepafenac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nepafenac.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Nepafenac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nepafenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNepafenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNepafenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Celecoxib.Approved, Investigational
CeliprololNepafenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNepafenac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nepafenac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nepafenac.Approved
CinoxacinNepafenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidNepafenac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nepafenac.Vet Approved
CloranololNepafenac may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Nepafenac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nepafenac.Experimental
CyclosporineNepafenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateNepafenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNepafenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNepafenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNepafenac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinNepafenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Nepafenac.Experimental
DesirudinNepafenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nepafenac.Approved, Investigational
DextranNepafenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nepafenac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nepafenac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nepafenac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNepafenac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nepafenac.Approved, Vet Approved
DicoumarolNepafenac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Nepafenac is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nepafenac.Approved
DihydrostreptomycinNepafenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nepafenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nepafenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nepafenac.Approved
DoxorubicinNepafenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNepafenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Nepafenac is combined with E-6201.Investigational
Edetic AcidNepafenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNepafenac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nepafenac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nepafenac.Approved
EnoxacinNepafenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNepafenac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nepafenac.Experimental
EpanololNepafenac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Nepafenac is combined with Epirizole.Approved
EpirubicinNepafenac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNepafenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nepafenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nepafenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Nepafenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Equilin.Approved
EsmololNepafenac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Estrone sulfate.Approved
Etacrynic acidNepafenac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateNepafenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Nepafenac is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Nepafenac is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nepafenac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Feprazone.Experimental
Ferulic acidNepafenac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nepafenac.Approved, Investigational
FleroxacinNepafenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nepafenac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fludrocortisone.Approved
FluindioneNepafenac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNepafenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nepafenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nepafenac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nepafenac.Approved, Nutraceutical, Vet Approved
FondaparinuxNepafenac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNepafenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nepafenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nepafenac.Approved
FramycetinNepafenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNepafenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNepafenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNepafenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNepafenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nepafenac.Approved, Withdrawn
GemifloxacinNepafenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNepafenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNepafenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANepafenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Nepafenac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNepafenac may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Nepafenac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nepafenac is combined with HE3286.Investigational
HeparinNepafenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Higenamine.Investigational
HydralazineNepafenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nepafenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nepafenac.Approved, Investigational
Hygromycin BNepafenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Nepafenac is combined with Icatibant.Approved
IdarubicinNepafenac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNepafenac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nepafenac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nepafenac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac.Approved
IndenololNepafenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.Approved, Investigational
IsepamicinNepafenac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nepafenac is combined with Istaroxime.Investigational
KanamycinNepafenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nepafenac.Approved
LabetalolNepafenac may decrease the antihypertensive activities of Labetalol.Approved
LandiololNepafenac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nepafenac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nepafenac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Leflunomide.Approved, Investigational
LepirudinNepafenac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNepafenac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNepafenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNepafenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Nepafenac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nepafenac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nepafenac.Approved
LonazolacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nepafenac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nepafenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Masoprocol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Nepafenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mefenamic acid.Approved
MelagatranNepafenac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Meloxicam.Approved, Vet Approved
MepindololNepafenac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineNepafenac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Nepafenac is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nepafenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNepafenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.Approved
MetoprololNepafenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNepafenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinNepafenac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nepafenac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nepafenac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nepafenac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nabumetone.Approved
NadololNepafenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNepafenac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNepafenac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Naftifine.Approved
Nalidixic AcidNepafenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Nepafenac is combined with NCX 1022.Investigational
NeamineNepafenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNepafenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinNepafenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNepafenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NetilmicinNepafenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nitroaspirin.Investigational
NorfloxacinNepafenac may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nepafenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Olopatadine.Approved
OlsalazineNepafenac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Nepafenac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nepafenac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Orgotein.Vet Approved
OtamixabanNepafenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Oxaprozin.Approved
Oxolinic acidNepafenac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNepafenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Parecoxib.Approved
ParomomycinNepafenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Parthenolide.Investigational
PazufloxacinNepafenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNepafenac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNepafenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNepafenac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateNepafenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nepafenac.Approved
PhenindioneNepafenac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNepafenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pimecrolimus.Approved, Investigational
PindololNepafenac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidNepafenac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNepafenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNepafenac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pirfenidone.Approved, Investigational
Piromidic acidNepafenac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pirprofen.Experimental
Platelet Activating FactorNepafenac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNepafenac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNepafenac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nepafenac.Approved
PractololNepafenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nepafenac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Nepafenac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Propacetamol.Approved, Investigational
PropranololNepafenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nepafenac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nepafenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nepafenac.Vet Approved
Protein CNepafenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanNepafenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNepafenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNepafenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Nepafenac is combined with PTC299.Investigational
PuromycinNepafenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nepafenac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nepafenac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nepafenac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nepafenac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinNepafenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNepafenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Risedronate.Approved, Investigational
RivaroxabanNepafenac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinNepafenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinNepafenac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNepafenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nepafenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nepafenac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nepafenac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Nepafenac.Approved
SemapimodThe risk or severity of adverse effects can be increased when Nepafenac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Nepafenac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Nepafenac is combined with Serrapeptase.Investigational
SisomicinNepafenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNepafenac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Nepafenac.Approved
SotalolNepafenac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNepafenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNepafenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNepafenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nepafenac.Approved
SRT501The risk or severity of adverse effects can be increased when Nepafenac is combined with SRT501.Investigational
StreptomycinNepafenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNepafenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Sulindac.Approved
SulodexideNepafenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nepafenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Suxibuzone.Experimental
TacrolimusNepafenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nepafenac.Approved
TalinololNepafenac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nepafenac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nepafenac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nepafenac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nepafenac.Approved, Investigational
TemafloxacinNepafenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nepafenac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Teriflunomide.Approved
TertatololNepafenac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNepafenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tixocortol.Approved, Withdrawn
TobramycinNepafenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolmetin.Approved
TorasemideNepafenac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nepafenac.Approved
TranilastThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nepafenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nepafenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nepafenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNepafenac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nepafenac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Nepafenac is combined with Triptolide.Investigational
TrovafloxacinNepafenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNepafenac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nepafenac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Nepafenac is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinNepafenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nepafenac.Approved
WarfarinNepafenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNepafenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Nepafenac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinNepafenac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNepafenac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857]
  2. Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [PubMed:10850858]
  3. Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8. [PubMed:17189793]
  4. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. [PubMed:17720067]
  5. Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019. [PubMed:18655957]
External Links
Human Metabolome Database
HMDB0015678
KEGG Drug
D05143
PubChem Compound
151075
PubChem Substance
99443294
ChemSpider
133160
ChEBI
75922
ChEMBL
CHEMBL1021
PharmGKB
PA165958407
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nepafenac
ATC Codes
S01BC10 — Nepafenac
AHFS Codes
  • 52:08.20 — Nonsteroidal Anti-inflammatory Agents
FDA label
Download (119 KB)
MSDS
Download (58.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionMacular Edema (ME)1
2CompletedTreatmentCataracts1
2CompletedTreatmentMacular Edema (ME) / Retinopathy, Diabetic1
2Unknown StatusPreventionMacular Edema (ME) / Macular Thickening1
2Unknown StatusTreatmentCataracts1
2WithdrawnTreatmentConjunctivitis, Bacterial1
3CompletedTreatmentCataracts5
3CompletedTreatmentCataracts / Non-Proliferative Diabetic Retinopathy2
3TerminatedTreatmentRetinopathy, Diabetic1
3Unknown StatusTreatmentDiabetic Macular Edema (DME)1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableCataracts1
4CompletedNot AvailableIntraocular Pressure1
4CompletedNot AvailableVitrectomy therapy1
4CompletedPreventionCataracts1
4CompletedPreventionCystoid Macular Edema1
4CompletedPreventionEpiretinal Membrane1
4CompletedPreventionMacular Edema (ME)1
4CompletedTreatmentCataracts2
4CompletedTreatmentCataracts / Cystoid Macular Edema1
4CompletedTreatmentDiabetic Macular Edema (DME)1
4CompletedTreatmentHypermetropia / Myopia1
4CompletedTreatmentInflammatory Reaction / Pseudophakia1
4CompletedTreatmentIntraocular Pressure1
4CompletedTreatmentPhotorefractive Keratectomy1
4Not Yet RecruitingTreatmentCystoid Macular Edema / Macular Edema (ME) / Uveitis1
4Unknown StatusTreatmentCataracts1
4Unknown StatusTreatmentPain1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentCystoid Macular Edema1
Not AvailableNot Yet RecruitingTreatmentGlaucoma, Angle-Closure / Glaucoma, Closed-Angle / Glaucoma, Narrow-Angle1
Not AvailableRecruitingNot AvailableInflamation Management / Pain Management / Post Surgical Management1
Not AvailableRecruitingTreatmentCataracts / Inflammatory Reaction / Retinal Edema1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionOphthalmic0.3 %
SuspensionOphthalmic3 mg/mL
SuspensionOphthalmic0.1 %
SuspensionOphthalmic1 mg/mL
Suspension / dropsOphthalmic1 mg/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7834059No2007-01-312027-01-31Us
US8071648No2005-12-022025-12-02Us
US8324281No2005-12-022025-12-02Us
US7947295No2004-06-082024-06-08Us
US6403609No1998-07-172018-07-17Us
US8921337No2012-03-312032-03-31Us
US9662398No2010-12-012030-12-01Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0197 mg/mLALOGPS
logP1.53ALOGPS
logP2.08ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.82ChemAxon
pKa (Strongest Basic)1.83ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.46 m3·mol-1ChemAxon
Polarizability26.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9624
Blood Brain Barrier+0.9918
Caco-2 permeable+0.5581
P-glycoprotein substrateNon-substrate0.7608
P-glycoprotein inhibitor INon-inhibitor0.5471
P-glycoprotein inhibitor IINon-inhibitor0.9209
Renal organic cation transporterNon-inhibitor0.8641
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.827
CYP450 3A4 substrateNon-substrate0.6542
CYP450 1A2 substrateInhibitor0.6993
CYP450 2C9 inhibitorInhibitor0.547
CYP450 2D6 inhibitorNon-inhibitor0.882
CYP450 2C19 inhibitorInhibitor0.5714
CYP450 3A4 inhibitorNon-inhibitor0.7118
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7441
Ames testNon AMES toxic0.6193
CarcinogenicityNon-carcinogens0.6932
BiodegradationNot ready biodegradable0.719
Rat acute toxicity2.0064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9797
hERG inhibition (predictor II)Non-inhibitor0.7681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dr-1490000000-433d63cd52e5b86417da

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
Diphenylmethanes / Aryl-phenylketones / Phenylacetamides / Benzoyl derivatives / Aniline and substituted anilines / Vinylogous amides / Primary carboxylic acid amides / Amino acids and derivatives / Primary amines / Organopnictogen compounds
show 2 more
Substituents
Benzophenone / Aryl-phenylketone / Diphenylmethane / Phenylacetamide / Benzoyl / Aniline or substituted anilines / Aryl ketone / Vinylogous amide / Amino acid or derivatives / Carboxamide group
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid amide (CHEBI:75922)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857]

Drug created on September 14, 2010 10:21 / Updated on January 19, 2018 10:58